scholarly journals Awareness Mentality and Strategic Behavior in Science

2021 ◽  
Vol 6 ◽  
Author(s):  
Rafael Ball
Keyword(s):  
Decision Making ◽  
Research Funding ◽  
Strategic Behavior ◽  
Science Management ◽  
Reference Databases ◽  
Quantitative Assessments ◽  
Scientific Achievements

Acknowledgement of scientific achievements was and is essentially achieved through the citation of a publication. Increasingly, however, it is no longer just the publication itself that plays an important role, but also the degree of attention that a scientist achieves with this very publication. Thus, the importance of strategic behavior in science is progressing and an awareness mentality is spreading. In this paper, the causes and backgrounds of this development are discussed, identifying the use of reductionist, quantitative systems in science management and research funding, the loss of critical judgment and technocratic dominance, quantitative assessments used for decision making, altmetrics and the like as alternative views, the use of perception scores in reference databases and universities as well as ambitions of journals as main drivers. Besides, different forms of strategic behavior in science and the resulting consequences and impacts are being highlighted.

scholarly journals An Overview of Multi-Criteria Decision-Making Methods in Dealing with Sustainable Energy Development Issues

Energies ◽  
2018 ◽  
Vol 11 (10) ◽  
pp. 2754 ◽  
Author(s):  
Indre Siksnelyte ◽  
Edmundas Zavadskas ◽  
Dalia Streimikiene ◽  
Deepak Sharma
Keyword(s):  
Decision Making ◽  
Swot Analysis ◽  
Sustainable Energy ◽  
Energy Development ◽  
Decision Makers ◽  
Multi Criteria Decision Making ◽  
Energy Sustainability ◽  
Widespread Application ◽  
Sustainability Problems ◽  
Scientific Achievements

The measurement of sustainability is actively used today as one of the main preventative instruments in order to reduce the decline of the environment. Sustainable decision-making in solving energy issues can be supported and contradictory effects can be evaluated by scientific achievements of multi-criteria decision-making (MCDM) techniques. The main goal of this paper is to overview the application of decision-making methods in dealing with sustainable energy development issues. In this study, 105 published papers from the Web of Science Core Collection (WSCC) database are selected and reviewed, from 2004 to 2017, related to energy sustainability issues and MCDM methods. All the selected papers were categorized into 9 fields by the application area and into 10 fields by the used method. After the categorization of the scientific articles and detailed analysis, SWOT analysis of MCDM approaches in dealing with sustainable energy development issues is provided. The widespread application and use of MCDM methods confirm that MCDM methods can help decision-makers in solving energy sustainability problems and are highly popular and used in practice.

scholarly journals Facilitating Team-Based Care Coordination and Collaboration in Myelofibrosis: Findings from a Quality Improvement Study in Three US Community Oncology Systems

Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 32-33
Author(s):  
Srdan Verstovsek ◽  
Anne Jacobson ◽  
Jeffrey D Carter ◽  
Tamar Sapir
Keyword(s):  
Decision Making ◽  
Quality Improvement ◽  
Patient Education ◽  
Care Coordination ◽  
Research Funding ◽  
Practice Patterns ◽  
Patient Centered Care ◽  
Patient Centered ◽  
Community Oncology ◽  
Centered Care

Background Care coordination can be especially challenging in the setting of rare malignancies such as myelofibrosis (MF), where hematology/oncology teams have limited experience working together to implement rapidly evolving standards of care. In this quality improvement (QI) initiative, we assessed barriers to patient-centered MF care in 3 community oncology systems and conducted team-based audit-feedback (AF) sessions within each system to facilitate improved care coordination. Methods Between 1/2020 and 3/2020, 31 hematology/oncology healthcare professionals (HCPs) completed surveys designed to characterize self-reported practice patterns, challenges, and barriers to collaborative MF care in 3 community oncology systems (Table 1). Building on findings from the team-based surveys, 39 HCPs from these centers participated in AF sessions to reflect on their own practice patterns and to prioritize areas for improved MF care delivery. Participants developed team-based action plans to overcome identified challenges, including barriers to effective risk stratification, care coordination, and shared decision-making (SDM) for patients with MF. Surveys conducted before and after the small-group AF sessions evaluated changes in participants' beliefs and confidence in delivering collaborative, patient-centered MF care. Results Team-Based Surveys: HCPs identified managing MF-associated anemia and other disease symptoms (42%), providing individualized care despite highly variable clinical presentations (29%), and developing institutional expertise despite low patient numbers (16%) as the most pressing challenges in MF care. For patients who are candidates for JAK inhibitor therapy, HCPs reported most commonly relying on current guidelines (71%) and clinical evidence (61%) to guide treatment selection. HCPs also considered drug safety/tolerability profiles (55%), personal or institutional experience (13%), and out-of-pocket costs for patients (13%); no participants (0%) reported incorporating patient preference into their decision-making. Teams were underutilizing SDM and patient-centered care resources; fewer than 50% reported providing tools to support adherence (48%), visual aids for patient education (47%), financial toxicity counseling (40%), resources for managing MF-related fatigue (36%), or counseling to reduce risk factors for CVD, bleeding, and thrombosis (26%). Small-Group AF Sessions: Across the 3 oncology centers, teams participating in the AF sessions (Table 1) shared a self-reported caseload of 97 patients with MF per month. HCPs reported a meaningful shift in beliefs regarding the importance of collaborative care: following the AF sessions, 100% of HCPs agreed or strongly agreed that collaboration across the extended oncology care team is essential for achieving MF treatment goals, an increase from 71% prior to the AF sessions (Figure 1). Participants also reported increased confidence in their ability to perform each of 6 aspects of evidence-based, collaborative, patient-centered care (Figure 2). In selecting which aspects of patient-centered care to address with their clinical teams, HCPs most commonly prioritized individualizing treatment decision-making based on patient- and disease-related factors (57%), followed by providing adequate patient education about treatment options and potential side effects (24%) and engaging patients in SDM (18%). To achieve these goals, 73% of HCPs committed to sharing their action plans with additional clinical team members; others committed to creating a quality task force to oversee action-plan implementation (15%) and securing buy-in from leadership and stakeholders (9%). Conclusions As a result of participating in this community-based QI initiative, hematology/oncology HCPs demonstrated increased confidence in their ability to deliver patient-centered MF care and improved commitment to team-based collaboration. Remaining practice gaps and challenges can inform future QI programs. Study Sponsor Statement The study reported in this abstract was funded by an independent educational grant from Incyte Corporation. The grantors had no role in the study design, execution, analysis, or reporting. Disclosures Verstovsek: ItalPharma: Research Funding; CTI Biopharma Corp: Research Funding; Promedior: Research Funding; Gilead: Research Funding; NS Pharma: Research Funding; Celgene: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Genentech: Research Funding; Sierra Oncology: Consultancy, Research Funding; PharmaEssentia: Research Funding; AstraZeneca: Research Funding; Incyte Corporation: Consultancy, Research Funding; Blueprint Medicines Corp: Research Funding; Protagonist Therapeutics: Research Funding; Roche: Research Funding.

scholarly journals Patient participation in research funding: an overview of when, why and how amongst Dutch health funds

2019 ◽  
Vol 5 (1) ◽  
Author(s):  
Willemijn M. den Oudendammer ◽  
Jacquelien Noordhoek ◽  
Rebecca Y. Abma-Schouten ◽  
Lieke van Houtum ◽  
Jacqueline E. W. Broerse ◽  
...  
Keyword(s):  
Decision Making ◽  
Patient Participation ◽  
Research Funding ◽  
Strategic Decision ◽  
Patient Organisation ◽  
Related Research ◽  
Dutch Health ◽  
Health Related Research ◽  
Health Related ◽  
Stage 1

Abstract Background Patient participation in decision-making on health-related research has gained ground. Nineteen Dutch health-related research-funding organisations (HFs) have taken up the challenge to include patients in their funding process. A ‘Patient participation (PP) advisory team’ was set-up, with HF-representatives and patient advocates, who together initiated this study. We provide an overview of when, why, and how PP activities take place in HFs’ funding processes, share main challenges and identify possible solutions. Methods A qualitative research design was used. Data was gathered by questionnaires (n = 14) and semi-structured interviews (n = 18) with HF employees responsible for patient participation, followed by a workshop (n = 27) with involved employees of HFs and key players in PP from national patient organisations and research organisations. A descriptive analysis was used for the questionnaire. A semi-directed content analysis was used for the interviews and the workshop. Results Three stages can be identified in the funding process in which HFs carry out PP activities: (1) strategic decision-making about focus of research (e.g. shared research agendas); (2) call for and receipt of research proposals (e.g. mandatory inclusion of letter of recommendation from patient organisation); (3) decision-making about the funding of research proposals (e.g. patients reside in a patient panel to co-review research proposals). Main challenges identified to carry out PP activities include: how to accommodate diversity of the patient body (mainly encountered in stage 1 and 3); to what extent should patients receive training to successfully participate (mainly encountered in stage 1 and 3); and who is responsible for patient-researcher dialogues (mainly encountered in stage 1 and 2). All nineteen HFs agree that patients should be included in at least one stage of the funding process for health-related research. CONCLUSION: Further broadening and optimising patient involvement is still needed. The proposed solutions to the identified challenges could serve as inspiration for national and international research funding foundations that aim to structurally include patients in their funding process.

How Research Funding Organizations can Increase Application of Science to Decision-Making

2011 ◽  
Vol 39 (3) ◽  
pp. 336-350 ◽  
Author(s):  
C. Riley ◽  
K. Matso ◽  
D. Leonard ◽  
J. Stadler ◽  
D. Trueblood ◽  
...  
Keyword(s):  
Decision Making ◽  
Research Funding

scholarly journals Effects of the COVID-19 Pandemic on Caregivers of Young Children with Sickle Cell Disease Enrolled in the Engage-HU Trial

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 1891-1891
Author(s):  
Anna M Hood ◽  
Aimee K Hildenbrand ◽  
Joanna Rebitski ◽  
Jasmine Stallworth ◽  
Yolanda Johnson ◽  
...  
Keyword(s):  
Decision Making ◽  
Sickle Cell Disease ◽  
Shared Decision Making ◽  
Sickle Cell ◽  
Research Funding ◽  
The United States ◽  
Data Safety Monitoring Board ◽  
Shared Decision ◽  
Cell Disease ◽  
Grant Funding

Abstract Background: Hydroxyurea (HU) is the primary medication used to prevent the significant medical and neurologic morbidities of pediatric sickle cell disease (SCD; HbSS or HbSB0 thalassemia). Despite the benefits of HU, it remains under-utilized likely due to lack of clinician knowledge/training and negative caregiver perceptions. Thus, we developed the Engage-HU randomized controlled trial (NCT03442114) as a novel approach to address HU utilization barriers. Engage-HU is designed to assess how clinicians can engage caregivers in a shared discussion that considers their values, preferences, and scientific evidence about HU. The COVID-19 pandemic has resulted in significant changes to healthcare delivery for children with SCD, as they are at increased risk of severe illness from COVID-19 infection. Given their risk status, it was recommended that patients with SCD complete telehealth visits when possible. Some families also chose to delay care because they feared their child would get infected at hospitals/healthcare clinics that care for COVID-19 positive patients. Since the lives of all families enrolled in the Engage-HU trial have been affected to some extent, we incorporated measures to capture the impact of the COVID-19 pandemic and the usability of telemedicine implementation and services. Methods: Engage-HU is a randomized control trial comparing two dissemination methods for clinicians to facilitate shared decision-making with caregivers of young children with SCD. Study outcomes include caregiver confidence in decision-making and perceptions of experiencing shared decision-making as well as HU uptake and child health outcomes. Eligible children are 0 to 5 years, candidates for HU, and their caregiver has not decided about HU in the past 3 months. The trial is being conducted at 9 sites in the United States and uses a unidirectional crossover design. The primary endpoints are caregiver decisional uncertainty and caregiver perception of shared decision-making measured using validated tools. Data will be analyzed using the intent-to-treat principle, and all participants will remain in the arm to which they were randomized. A multiple group comparison analysis will be performed to assess significant response variable differences by group randomization. The Engage-HU study aims to recruit 174 caregivers who are considering initiating HU. The trial is being conducted at 9 sites in the United States. Data collection is ongoing, and 160 caregiver-participants have been enrolled to date. Since May 2020, caregiver-participants have completed the COVID-19 Exposure and Family Impact Scales (CEFIS), which contain 2 subscales (exposure to potentially traumatic aspects of the pandemic, impact on families), and the COVID-19 telemedicine use survey during a study visit. Results: Currently, 8 of the 9 sites have collected data from 48 caregivers (93.8% mothers), most of whom (93.8%) identify as African American/Black (see Figure 1). Correlations indicated that older caregivers experienced greater exposure (Mean = 7.0, SD = 4.1, range = 1-19) to potentially traumatic aspects of the pandemic (r = .31, p = .04). Distress related to COVID-19 varied widely across the sample, for both caregivers (Mean = 5.9, SD = 2.9, range = 1-10) and children (Mean = 4.1, SD = 3.4, range = 1-10). Scores on the telemedicine usability survey were generally high, indicating that caregivers are happy with the quality of care delivered via telehealth. However, caregivers (r = .30, p = .09) and children (r = .32, p = .07) experiencing more pandemic-related distress reported less satisfaction with telehealth. Conclusion: Although Engage-HU has resumed research operations, recruitment has not reached pre-pandemic targets, as fewer eligible patients are scheduled for routine care visits at SCD clinics. Our preliminary analyses suggest a significant continued impact of the pandemic on families and general satisfaction with the quality of healthcare delivered via telemedicine. These findings indicate that targeted screenings to identify and intervene for those who demonstrate more COVID-19 pandemic-related distress are needed. Figure 1 Figure 1. Disclosures Quinn: Forma Therapeutics: Consultancy; Aruvant: Research Funding; Novo Nordisk: Consultancy; Emmaus Medical: Research Funding. Yates: Agios Pharmaceuticals: Current Employment. Badawy: Sanofi Genzyme: Consultancy; Vertex Pharmaceuticals Inc: Consultancy; Bluebird Bio Inc: Consultancy. Thompson: bluebird bio, Inc.: Consultancy, Research Funding; Baxalta: Research Funding; Biomarin: Research Funding; Celgene/BMS: Consultancy, Research Funding; CRISPR Therapeutics: Research Funding; Vertex: Research Funding; Editas: Research Funding; Graphite Bio: Research Funding; Novartis: Research Funding; Agios: Consultancy; Beam: Consultancy; Global Blood Therapeutics: Current equity holder in publicly-traded company. Smith-Whitley: Global Blood Therapeutics: Current Employment. King: National Cancer Institute: Research Funding; National Heart, Lung, and Blood Institute: Research Funding; Health Resources and Services Administration: Research Funding; Global Blood Therapeutics: Research Funding. Meier: CVS Caremark: Consultancy; Forma Therapeutic: Membership on an entity's Board of Directors or advisory committees; NovoNordisk: Membership on an entity's Board of Directors or advisory committees; Novartis,: Other: Data Safety Monitoring Board membership; NHLBI: Other: Data Safety Monitoring Board membership; Global Blood Therapeutics: Other: Steering Committee membership, grant funding; CDC,: Other: grant funding; Indiana Department of Health: Other: grant funding . Tubman: Global Blood Therapeutics: Consultancy, Research Funding; Novartis Pharmaceuticals: Honoraria, Research Funding; Forma Pharmaceuticals: Consultancy; Perkin Elmer: Honoraria. Crosby: Forma Therapeutics: Honoraria; PCORI: Research Funding; HRSA: Research Funding; Global Blood Therapeutics Panel: Honoraria; Children's Hospital of Philadelphia: Honoraria; Professional Resource Exchange: Patents & Royalties: $30-$60 every other year; SCDAA: Honoraria; NHLBI: Other: Payment for review of LRP Proposals, Research Funding. OffLabel Disclosure: Hydroxyurea has been FDA approved for the treatment of sickle cell disease for patients ages 2 years and above but NHLBI and ASH Guidelines recommend it be offered to children as young as age 9 months.

scholarly journals Treatment Decision Making and Treatment Satisfaction Among Individuals Living with Chronic Myeloid Leukemia

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 4787-4787
Author(s):  
Julie Olson ◽  
Shauna McManus ◽  
Melissa F. Miller ◽  
Thomas W. LeBlanc ◽  
Eva Yuen ◽  
...  
Keyword(s):  
Decision Making ◽  
Treatment Outcomes ◽  
Board Of Directors ◽  
Research Funding ◽  
Treatment Options ◽  
Treatment Decision ◽  
Treatment Decisions ◽  
Advisory Committees ◽  
Treatment Decision Making ◽  
Satisfaction With Treatment

Abstract Background: Over the past decade, an increase in treatment options for chronic myeloid leukemia (CML) has dramatically changed the therapeutic landscape and has improved clinical outcomes. This abundance of treatment options may make it difficult for CML patients to feel knowledgeable about what options are available to them, may hinder patients' preparedness for having conversations about treatment, and, similarly, may contribute to patients feeling less involved in treatment decision making (TDM). In light of this changing landscape, we explored whether the TDM experience was linked to satisfaction with treatment outcomes in a national sample of CML patients. Methods: Using data from the Cancer Support Community's Cancer Experience Registry®, our analytic sample included 310 participants who reported CML as their primary diagnosis. The dependent variable in all analyses was a dichotomous, patient-reported indicator of satisfaction with treatment outcomes (satisfied or not satisfied). Our independent variables include three measures that capture the TDM experience: feeling involved in the TDM process; feeling knowledgeable about treatment options prior to making treatment decisions; and, feeling prepared to discuss treatment options with one's doctor. Respondents ranked TDM knowledge, preparedness, and involvement from 0 = "not at all" to 4 = "very much." Responses were dichotomized such that 1 = "quite a bit" or "very much" and 0 = "not at all," "a little bit" or "somewhat." Analytically, we compared patients who reported high satisfaction with treatment outcomes to those who reported low satisfaction, using Student's t-test. Then, we estimated multivariate logistic regression models predicting odds of being satisfied with treatment outcome by TDM knowledge, preparedness, and involvement. Regression models controlled for demographic characteristics including age, gender, and race; clinical factors such as time since diagnosis and symptom burden; treatment-related measures including financial impact of treatment; and the degree to which individuals felt their health care teams prepared them to manage treatment side effects. Results: Descriptively, our sample was 65% female and 87% non-Hispanic White, with an average age of 56.6 years (SD = 12) and mean time since diagnosis of 6 years (SD = 5). Most (74%) reported being "quite a bit" to "very much satisfied" with their treatment outcomes. Experiences with TDM, however, were variable. When making treatment decisions, 52% reported feeling involved, 41% reported feeling knowledgeable, and 21% felt prepared. Importantly, t-test results suggested that individuals with greater involvement, more knowledge, and higher preparedness were significantly more likely to report satisfaction with treatment outcomes. Results of the multivariate models demonstrated a greater likelihood of treatment satisfaction among individuals who felt prepared to discuss treatment options with their health care team, even after controlling for demographic, clinical, and treatment-related characteristics. In fact, prepared individuals were nearly 6 times as likely to be satisfied with their treatment outcomes, as compared to individuals who did not feel prepared to discuss treatment options (p < .05). Conclusion: Most of our patients with CML did not feel prepared to make treatment decisions. However, those who feel more prepared to discuss treatment options with their doctors are also more likely to report satisfaction with treatment outcomes. As new CML treatment options become available, our results highlight the need for an increased focus on shared decision making in clinical practice. This may necessitate providing patients with more resources to help prepare them for treatment-related conversations. Disclosures Birhiray: Takeda: Research Funding, Speakers Bureau; Genomic Health: Patents & Royalties; Amgen: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Alexion: Consultancy; Puma: Research Funding, Speakers Bureau; Pharmacyclics: Speakers Bureau; Janssen: Consultancy, Speakers Bureau; Bristol Myers Squibb: Speakers Bureau; Norvatis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Bayer: Membership on an entity's Board of Directors or advisory committees; Eli-Lilly: Speakers Bureau; Excelis: Speakers Bureau; Clovis Oncology: Speakers Bureau; Sanofi Oncology: Speakers Bureau; Incyte: Speakers Bureau; AstraZeneca: Speakers Bureau; Tessaro: Speakers Bureau; Pfizer: Speakers Bureau; Celgene: Membership on an entity's Board of Directors or advisory committees; Helsinn: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees.

scholarly journals A társadalomföldrajzi folyóiratok rangsorának alakulása a Scimago adatbázisa alapján

2021 ◽  
Vol 16 (4) ◽  
pp. 49-68
Author(s):  
Tamás Kovalcsik ◽  
◽  
György Vida ◽  
Lajos Boros ◽  
◽  
...  
Keyword(s):  
Relative Position ◽  
Web Of Science ◽  
Human Geography ◽  
Anglo Saxon ◽  
Journal Rankings ◽  
Reference Databases ◽  
Scientific Life ◽  
Scientific Achievements ◽  
Research Resources

One of the main consequences of the neoliberalization of scientific life is the growing demand for measurement and comparability of scientific achievements, not only by the academia but also by society as a financier and the economy as a customer. Thus, more and more attention is being paid to journal rankings created by prestigious (and generally Anglo-Saxon-dominated) reference databases (Web of Science or Scimago) that make this possible. They play a key role in the allocation of research resources; the promotion of researchers thus also influences the publication strategies. The study aims to explore the changes and certain spatial aspects in rankings within the Geography, Planning and Development category. The research is based on the analysis of the quartile classification of human geography journals indexed in the Scimago database. Our results show what are the factors that influence the relative position of a particular journal, and through this, the indicators of researcher success.

scholarly journals Patients Experience of Living with Cancer Associated Thrombosis in France (LE PELICAN)

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 3684-3684
Author(s):  
Isabelle Mahe ◽  
Annmarie Nelson ◽  
Jean Chidiac ◽  
Parinata Swarnkar ◽  
Mickael Pinson ◽  
...  
Keyword(s):  
Decision Making ◽  
Shared Decision Making ◽  
Research Funding ◽  
Medical Attention ◽  
Shared Decision ◽  
Structured Interviews ◽  
Software Analysis ◽  
Information Giving ◽  
Cancer Associated Thrombosis ◽  
Patients Experience

Introduction Previous research from the Europe and Canada has identified several areas of unmet clinical and support need for cancer patients diagnosed with venous thromboembolism (VTE). It is not known whether such experiences are restricted to those particular countries healthcare systems and/ or cultures. We sought to evaluate patients' experience of cancer-associated thrombosis (CAT) within France. Methods Purposive sampling of twenty three patients with CAT were recruited from a thrombosis service in a general hospital in Colombes, France, Semi structured interviews were audio recorded and transcribed. Transcripts were coded using Invivo software. Analysis was undertaken using an applied framework matrix with an inductive approach to identify any new themes. This was in order to explicate potential cultural and operational differences that were not apparent in the previous datasets. Results Twenty three patients (11 male, 13 female) aged 51-83 (mean 69) participated. The main commonality observed between French patients and those interviewed in the United Kingdom, Spain and Canada was the lack of information regarding the risks of CAT or signs and symptoms, which would necessitate medical attention. In addition patients reported a similar lack of verbal and written information regarding treatment choices and how to administer low molecular weight heparin (LMWH). However, French patients were not concerned by this since they perceived the doctor knew best and did not see information giving as a necessary aspect of their healthcare. They adopted a passive unquestioning role whereby the doctor was always right. This lack of desire to understand about their condition and in particular CAT, resulted in two major themes which are , thus far, have only been observed in this cohort of patients. 1. Lack of understanding and desire to know about CAT meant that patients knew less about their condition than other patients. Whereas patients from other countries were significantly distressed by knowing the potentially fatal nature of CAT, French patients were not distressed by their diagnosis, its implications on their cancer journey or the future. 2. Patients did not appreciate the utility of shared decision making and relied on the doctor to decide on the drug of choice. They did not wish to understand the rationale for this and thereby did not view the LMWH as a necessary inconvenience. Consequently they were very resistant to LMWH. Conclusion The dynamics of the doctor patient relationship in French patients differed from other countries, with patients adopting a passive role with respect to information requirements and their role in shared decision making. This dynamic appears to be a "two edged sword" whereby distress around CAT was minimal, in contrast to all other countries interviewed, yet a lack of knowledge impacted on acceptability of LMWH patient groups. This data has implications for the choice of anticoagulant in the treatment of CAT, particularly now that several DOACS have been evaluated for this indication. Disclosures Mahe: Leo Pharma: Research Funding, Speakers Bureau; BMS: Research Funding, Speakers Bureau; Bayer: Speakers Bureau; Pfizer: Speakers Bureau. Noble:Leo Pharma: Research Funding; Daiichi Sankyo: Speakers Bureau; Bayer: Speakers Bureau; Pfizer: Speakers Bureau.

Strategies for Network Industries

2013 ◽  
pp. 301-324
Author(s):  
Oz Shy
Keyword(s):  
Decision Making ◽  
Strategic Behavior ◽  
Design Stage ◽  
Network Industries ◽  
Technology Standards ◽  
Managerial Decision ◽  
Managerial Decision Making

Firms' strategic behavior and managerial decision-making in network industries may differ from those in other industries. This happens because an increase in the demand for one brand need not reduce the demand for competing brands. In addition, consumers may be locked-in a particular standard, so they may bear a cost of switching to competing brands. Therefore, starting as early as from the design stage, managers must evaluate the implications of their choices of prices, technology standards, and the degree of compatibility of their own brands with the standards adopted by firms producing competing brands. This article analyzes some of the major issues facing managers operating in modern network industries.

scholarly journals Borda Count in Collective Decision Making: A Summary of Recent Results

2019 ◽  
Vol 33 ◽  
pp. 9830-9836
Author(s):  
Jörg Rothe
Keyword(s):  
Artificial Intelligence ◽  
Decision Making ◽  
Strategic Behavior ◽  
Collective Decision ◽  
Borda Count ◽  
Collective Decision Making ◽  
Computational Social Choice ◽  
Indivisible Goods ◽  
Voting Rules ◽  
Ordinal Preferences

Borda Count is one of the earliest and most important voting rules. Going far beyond voting, we summarize recent advances related to Borda in computational social choice and, more generally, in collective decision making. We first present a variety of well known attacks modeling strategic behavior in voting—including manipulation, control, and bribery—and discuss how resistant Borda is to them in terms of computational complexity. We then describe how Borda can be used to maximize social welfare when indivisible goods are to be allocated to agents with ordinal preferences. Finally, we illustrate the use of Borda in forming coalitions of players in a certain type of hedonic game. All these approaches are central to applications in artificial intelligence.

Sign in / Sign up

Export Citation Format

Share Document